KUIK Family Focus 101 hosted by Diane Dennis
Dr. Jay Andersen discusses the benefits of the Oncotype DX assay test in women with early-stage (Stage I or II), node-negative, estrogen receptor-positive (ER+) invasive breast cancer who will be treated with hormone therapy. The test provides a more personalized evaluation of recurrence risk, identifying those patients who warrant inclusion of chemotherapy in addition to anti-hormone therapy as part of their treatment plan.
To listen to the interview, click here.